Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026
Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Fineline Cube May 9, 2026
Company Policy / Regulatory

China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables

Fineline Cube Sep 15, 2023

The national high-value medical consumables joint procurement office has released a notification, marking the commencement...

Company

J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation

Fineline Cube Sep 15, 2023

Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...

Company Drug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

Fineline Cube Sep 15, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...

Company Drug

AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC

Fineline Cube Sep 15, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...

Company Deals

Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis

Fineline Cube Sep 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery

Fineline Cube Sep 15, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Drug

Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine

Fineline Cube Sep 15, 2023

Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...

Company Deals

Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing

Fineline Cube Sep 15, 2023

China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD...

Company R&D

Jiangsu Aidea Pharmaceutical Partners with National Medical Center for Infectious Disease on HIV Drug Development

Fineline Cube Sep 15, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Drug

Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA

Fineline Cube Sep 15, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...

Company Medical Device

Genesis MedTech Receives Chinese Market Approval for Antibacterial Absorbable Sutures

Fineline Cube Sep 14, 2023

Singapore-based medical device company Genesis MedTech has announced that it has received market approval in...

Company Drug

Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study

Fineline Cube Sep 14, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...

Company Deals

Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion

Fineline Cube Sep 14, 2023

Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic...

Company Deals

Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan

Fineline Cube Sep 14, 2023

A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered...

Company Drug

Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review

Fineline Cube Sep 14, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab

Fineline Cube Sep 14, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...

Company Drug

AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results

Fineline Cube Sep 14, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...

Company Drug

InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment

Fineline Cube Sep 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...

Company Drug

EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Sep 14, 2023

The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...

Company Drug

FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease

Fineline Cube Sep 14, 2023

The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...

Posts pagination

1 … 469 470 471 … 662

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.